Glenmark Pharma’s (Glenmark) Q3FY23 performance was a beat vs our estimates, largely driven by better than expected RoW and EU performances. Revenue was up 9.2% YoY to Rs34.6bn (I-Sec: Rs31.4bn) led by healthy growth in the US, RoW and EU businesses.